Daraxonrasib Challenges Second-Line Pancreatic Cancer Care
Daraxonrasib showed promising survival in KRAS-mutant metastatic pancreatic cancer, but stronger randomized evidence is needed before replacing standard second-line chemotherapy.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.